1/1

FIEO Registered Export Ready

Auriliv-Silybum marianum and Andrographis paniculata Nanophosphosome®

Name: Auriliv-Silybum marianum and Andrographis paniculata Nanophosphosome®
Brand: aurinko
SKU: 8520869
Availability: InStoreOnly

Sold by aurinko healthcare pvt. ltd. · Manufacturer, Exporter · Faridabad, Haryana, India

Price

Price on request

In stock

Minimum order: 1 unit

Export Snapshot

MOQ

1 unit

Lead time

On request

Packaging

Standard export packaging

Shelf life / longevity

As per product specification

HSN Code

9027

Origin

India

Port of dispatch

On request

Export markets served

Global markets

Values shown are for aurinko healthcare pvt. ltd..

FIEO Registered

Suitable for

Importers · Distributors · Wholesalers

Faridabad Dispatch on request FIEO member

aurinko healthcare pvt. ltd.

Manufacturer, Exporter · Faridabad, Haryana, India

Registered address: Faridabad, India.

View profile All products

Established

Not shared

Employees

–

GST

06AANCA0380R1Z7

IEC code

Not shared

Export markets

Global markets

GlobalLinker Member Since

Not shared

Turnover

$1 MM - $2 MM

Incorporation Type

On request

Certifications & Awards

WHO-GMP HACCP ISO 9001:2015 (QMS) ISO 22000 2005(FSMS)

Product details

What are the specifications of this product?

Overview

Auriliv is a synergistic blend of Silybum marianum and Andrographis paniculata Nanophosphosome®, enhanced with advanced bioenhancer and metabolic potentiator technology to improve absorption, prevent metabolic reduction, and support optimal liver function through enhanced bioavailability and cellular transport mechanisms.

Product Description

Auriliv is a synergistic combination of Silybum marianum and Andrographis paniculata Nanophosphosome® (a nano- emulsified Silymarin - Andrographolide Phosphatidyl Choline - Serine - Ethanolamine complex) with technologically advanced bioenhancer and metabolic potentiator technology.Bioenhancer and metabolic activator technology enhances the passive diffusion and active transport mechanism through intestinal microvilli to improve actives’ absorption as well prevents their metabolic reduction through inhibition of P - gp efflux pump, ATPase activity, CYP3A4, CYP3AG and UGT

Description provided by aurinko healthcare pvt. ltd..

Specifications

Composition	Silymarin and Andrographolide complex with Phosphatidylcholine, Serine, Ethanolamine
Form	Nano-emulsified phospholipid complex
Absorption Enhancement	Inhibition of P-gp efflux, ATPase, CYP3A4, CYP3AG, UGT enzyme pathways
Targeted Organ	Liver
Dosage Form Compatibility	Suitable for incorporation into capsules, tablets, liquid formulations
Mechanism	Enhances active constituent permeability and metabolic stability
Stability	Enhanced stability due to nano-emulsification
Storage	Store in cool, dry place away from direct sunlight
Shelf Life	Typically 24 months when stored properly

Use cases

Category	Pharmaceutical Ingredients > Nutraceutical Ingredients > Liver Support Extracts
Primary application	Wholesale, distribution, and international sourcing
Brand	aurinko
Product type	Product

Logistics & handling

Lead time	On request
Packaging	As per buyer requirement
Storage condition	As recommended by supplier
Origin	India
Form	Nano-emulsified phospholipid complex

Commercials (this seller)

Minimum order	1 unit
Lead time	On request
Payment terms	As per negotiated commercial agreement.

Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing Auriliv-Silybum marianum and Andrographis paniculata Nanophosphosome®. Answers compiled from verified sellers' commercial terms and platform data.

Q: How does Auriliv improve the bioavailability of silymarin and andrographolide?

A: Auriliv uses a proprietary Nanophosphosome® nano-emulsified delivery system combined with bioenhancer technology that facilitates both passive diffusion and active transport across intestinal microvilli while inhibiting metabolic enzymes and efflux pumps responsible for drug degradation, thereby significantly enhancing the bioavailability of its active compounds.

Q: What role does metabolic potentiator technology play in Auriliv’s effectiveness?

A: The metabolic potentiator technology in Auriliv inhibits key enzymes like CYP3A4, CYP3AG, UGT, and the P-glycoprotein efflux pump, which typically metabolize and reduce the concentration of active phytochemicals, prolonging their presence in systemic circulation and increasing therapeutic efficacy.

Q: Is Auriliv suitable for formulation into different dosage forms?

A: Yes, Auriliv’s nano-emulsified Nanophosphosome® complex is stable and compatible with various dosage forms including capsules, tablets, and liquid nutraceutical products, allowing versatile application in pharmaceutical and nutraceutical manufacturing.

Q: What differentiates Auriliv from regular silymarin or andrographis extracts?

A: Unlike regular extracts, Auriliv combines both herbal actives into a patented nano-emulsified phospholipid complex with advanced bioenhancer and metabolic potentiator technologies, which significantly improves absorption, reduces metabolic loss, and promotes higher bioavailability, enhancing its liver support effects.

Q: How does Auriliv prevent metabolic reduction of its active ingredients?

A: Auriliv prevents metabolic reduction by inhibiting P-glycoprotein efflux pumps and metabolizing enzymes such as CYP3A4, CYP3AG, and UGT, which are responsible for the breakdown and clearance of silymarin and andrographolide, thus ensuring sustained therapeutic levels.

Question not answered? Ask sellers directly — typical response within 4 hours.